Ulrich: Treating Covid-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind, Randomized Controlled Trial in Hospitalized Patients [HCQ]

Treating Covid-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind, Randomized Controlled Trial in Hospitalized Patients

Ulrich et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofaa446, TEACH, NCT04369742 (history)

Ulrich et al., Treating Covid-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind, Randomized Controlled Trial in.., Open Forum Infectious Diseases, doi:10.1093/ofid/ofaa446, TEACH, NCT04369742

Sep 2020 Source PDF

Twitter
Facebook

All Studies Meta

Small RCT on very late stage use of HCQ, with 48% on oxygen at baseline. 67 HCQ patients, 61 control. Baseline states were not comparable - 82% more HCQ patients had the highest severity at baseline, there was 32% more male HCQ patients, and 44% more control patients used AZ. The HCQ group also had significantly more patients with cerebrovascular disease, cardiovascular disease (non-hypertension), renal disease (non-dialysis), and a history of organ transplants. This study is excluded in the after exclusion results of meta analysis: very late stage, >50% on oxygen/ventilation at baseline.

Important missing comments or errors? Let us know.

risk of death, 6.0% higher, RR 1.06, p = 1.00, treatment 7 of 67 (10.4%), control 6 of 61 (9.8%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Ulrich et al., 23 Sep 2020, Randomized Controlled Trial, USA, peer-reviewed, baseline oxygen required 63.3%, mean age 66.2, 18 authors, average treatment delay 7.0 days, trial NCT04369742 (history) (TEACH).

All Studies Meta Analysis Submit Updates or Corrections

This Paper HCQ All

Abstract: TREATING COVID-19 WITH HYDROXYCHLOROQUINE (TEACH): A MULTICENTER, DOUBLE-BLIND, RANDOMIZED CONTROLLED TRIAL IN HOSPITALIZED PATIENTS Robert J. Ulrich MD1,4,*, Andrea B. Troxel ScD3,7, Ellie Carmody MD, MPH1,4, Jaishvi Eapen MD1,4, Martin Bäcker MD10, Jack A. DeHovitz MD, MPH, MHCDS, FACP9, Prithiv J. Prasad Brooklyn Henderson RN1,4, Alexander Hrycko MD1,4, Dinuli Delpachitra MBBS10, Vanessa Raabe MD1,2,4,6,5, Jonathan S. Austrian MD1, Yanina Dubrovskaya PharmD, BCIDP1,4,11, and Mark J. Mulligan, MD, FIDSA1,4 1 Department of Medicine, New York University Grossman School of Medicine. New York, NY, USA. 2 Department of Pediatrics, New York University Grossman School of Medicine. New York, NY, USA. 3 Department of Population Health, New York University Grossman School of Medicine. New York, NY, USA. 4 Division of Infectious Diseases and Immunology, New York University Grossman School of Medicine. New York, NY, USA. 5 Divison of Pediatric Infectious Diseases, New York University Grossman School of Medicine. New York, NY, USA. 6 Division of Pediatric Hematology-Oncology, New York University Grossman School of Medicine. New York, NY, USA. 7 Division of Biostatistics, New York University Grossman School of Medicine. New York, NY, USA. 8 New York University Grossman School of Medicine. New York, NY, USA. 9 Department of Medicine, Division of Infectious Diseases, State University of New York Downstate Health Sciences University, Brooklyn, NY, USA. 10 Department of Medicine, Division of Infectious Diseases, NYU Long Island School of Medicine. Mineola, NY, USA. 11 Department of Pharmacy, NYU Langone Health. New York, NY, USA. *Corresponding Author: Robert J. Ulrich MD. 551 First Ave, New York NY 10016, United States. Email: robert.ulrich@nyulangone.org © The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons AttributionNonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com MBBS1,4, Yi Li MS3,7, Camila Delgado PhD8, Morris Jrada MD1, Gabriel A. Robbins MD2,6, Author Contributions: RJU, ABT, EC, VR and MJM contributed to the concept, design and protocol development. RJU, EC, JE, MB, JAD and PJP contributed as site leaders overseeing all trial operations and data quality from each site. MJ, GAR, BH, AH, DD and YD contributed to trial operations and data entry. RJU, ABT, CD, and YL contributed to data analysis. JSA created novel information technology for trial operations. RJU and ABT drafted the manuscript. All authors provided critical revisions and approved the final manuscript. Clinicaltrials.gov # NCT04369742 2 Abstract Background: Effective therapies to combat COVID-19 are urgently needed. Hydroxychloroquine (HCQ) has in vitro..

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit